- Home
- News
- canada newfoundland
- immune functional
Refine by
Immune Functional Articles & Analysis
28 news found
Responding to the surging global demand for specialized bioactive ingredients, the chemical and material supplier Alfa Chemistry has significantly expanded its catalogue of high-purity hydrolyzed protein peptides. The company now prominently features a diverse range, including sought-after marine-sourced peptides like Fish Collagen Peptide, Marine Fish Oligopeptide, Oyster Peptide, and Sea ...
BioZyme’s mission is to provide an undeniable positive impact on the health and wellness of the animals it serves. Therefore, BioZyme and its staff continually research and create products to help animals and maximize efficiencies for producers. With our mission and commitment to care that comes full circle in mind, we are excited to introduce VitaFerm® Sure Start Gel. VitaFerm Sure ...
Investorideas.com (www.investorideas.com) Biotech Stock News Bites - Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines is one of NASDAQ's top gainers today and the stock is trending on Yahoo Finance, currently trading at $3.8955, up $1.6955 or 77.0682%. The stock had a morning high of $5.47 on volume of over 36 Million/. The Company's CEO, ...
Alfa Chemistry, a reputable global supplier of research chemicals and materials, has recently announced the integration of its dietary supplement ingredients supply. This move aims to streamline the company's operations and enhance its ability to meet the growing demand for high-quality dietary supplement ingredients. Dietary supplements have gained significant popularity in recent years, with ...
Creative Enzymes, a leading provider of innovative enzymes and probiotic solutions, is proud to introduce a range of Lactobacillus strains with enhanced benefits that are designed to revolutionize the way we approach gut health. This high-quality probiotic powder not only offers a wide range of health benefits but also opens up new opportunities for the food and pharmaceutical industries. In ...
Regor Therapeutics, a clinical-stage biotech company, announced today the Investigational New Drug (IND) Application for RGT-264 phosphate tablet, a small molecular selective hematopoietic progenitor kinase (HPK1) inhibitor has been approved by the National Medical Products Administration (NMPA) of China. RGT-264 phosphate tablet is a highly potent and selective HPK1 inhibitor. HPK1 kinase ...
The Cytokine division belongs to Creative Proteomics, which specializes in providing cytokine research and analysis services for researchers in the pharmaceutical and biotechnology industries, as well as academic institutes and government agencies. Creative Proteomics Cytokine recently launched the Mouse Cytokine Assay with high sensitivity to support research in immune responses, inflammatory ...
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today a Cooperative Research and Development Agreement (CRADA) with the United States Department of Veterans Affairs (VA) for the addition of a Miami VA clinical site to its ongoing Phase 2 ...
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and other specific life-threatening conditions, announced today the addition of K. Chris Min, M.D., Ph.D. to the Longeveron executive leadership team in the role of Chief Medical Officer (CMO), effective April 4, 2022. Dr. Min will lead global ...
Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biopharma company developing cellular therapies for aging-related illnesses, chronic disorders, and other specific life-threatening conditions, announced the publication of results from a Phase 1 trial testing Lomecel-B on patients with mild Alzheimer’s disease (AD) in Alzheimer’s & Dementia®: The Journal of the ...
Prellis Biologics, Inc. (Prellis), a Bay Area biotechnology company, announced today that it has entered into a multi-target drug discovery collaboration and licensing agreement with Bristol Myers Squibb utilizing Prellis Biologics’ first-in-class externalized human immune system (EXIS) based on human lymph node organoids (LNO). The collaboration leverages Prellis’ EXIS platform that ...
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and certain life-threatening conditions, announced today publication of the design and rationale from its recently completed Phase 2b aging frailty clinical trial with Lomecel-B in the Journal of Frailty and Aging. This peer-reviewed ...
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and certain life-threatening conditions, announced today the initiation of its Phase 2a clinical trial evaluating Lomecel-B as a treatment for Alzheimer’s disease (AD). The first patient has consented to participate in the trial and ...
Synaffix to provide access to proprietary antibody-drug conjugate (ADC) technologies Genmab secures rights for conducting research on ADCs against multiple drug targets with options for exclusive worldwide development and commercialization of resulting therapies Synaffix to receive an upfront payment of USD $4.5 million with a total deal value of up to USD $415 million plus tiered single ...
GI Innovation, Inc., (CEO, Jun Ho Hong) announced that GI Innovation signed a clinical supply collaboration agreement with global biopharmaceutical company AstraZeneca for development of GI-101 and Imfinzi® combination therapy. Under this agreement, GI Innovation and AstraZeneca will conduct a clinical trial assessing triplet combination regimen of GI-101, Imfinzi® (durvalumab) and ...
Prellis Biologics announced today that it has closed a $14.5 million Series B financing round, led by Celesta Capital and current investor Khosla Ventures Prellis will use the proceeds to advance its Externalized Immune System (EXIS™) platform, a first-in-class in vitro, fully human antibody discovery, and vaccine screening workflow. “The EXIS platform offers unprecedented in vitro ...
Prellis Biologics announced today that it has closed a $14.5 million Series B financing round, led by Celesta Capital and current investor Khosla Ventures Prellis will use the proceeds to advance its Externalized Immune System (EXIS™) platform, a first-in-class in vitro, fully human antibody discovery, and vaccine screening workflow. “The EXIS platform offers unprecedented in vitro ...
Celularity Inc. (Nasdaq: CELU) (“Celularity”) presented preclinical data on the development of its placental-derived allogeneic genetically modified NK cell therapy program (CYNK-101) and its placenta-derived allogeneic CAR-NK cell therapy program (CAR19-CYNK), respectively. The Company reported its findings in two poster presentations at the 63rd American Society of ...
TOKYO and TEL AVIV, Israel, Sept. 30, 2021 /PRNewswire/ -- CytoReason, an AI company developing computational disease models for discovery and clinical drug development, and Summit Pharmaceuticals International (SPI), a Japanese company providing service and products to the pharmaceutical industry (wholly-owned subsidiary of Sumitomo Corporation), today announced that CytoReason has entered the ...
Immunai has taken some important steps toward its quest to map the entire immune system by completing its second acquisition this year and bolstering its management and board with new executive and entrepreneurial expertise. Immunai has acquired the Swiss-based biocuration and data integration company Nebion for an undisclosed sum. The deal should extend Immunai’s target discovery and drug ...
ByImmunai